Background: Research reports about molecular characterization of CTX M extended spectrum β-lactamases are fragmentary from Bahrain.
CTX M type extended-spectrum β-lactamases (ESBLs) are class A ESBLs showing resistance to third and fourth-generation cephalosporins and to aztreonam 1, 2 . Since the first discovery of CTX M 1 type ESBL, numerous variants of this ESBL have been reported. CTX M ESBLs are prevalent ESBLs worldwide and currently approaching 160 3 . Increasing prevalence of such ESBLs has put a pressure on clinical settings for increased usage of carbapenems; as a result carbapenem-resistance has also appeared [4] [5] [6] [7] . Although ESBL phenotypes have been reported from Bahrain, the reports pertaining to molecular characterization of such an important class of ESBLs are fragmentary.
The aim of this pilot study is to characterize the Gram-negative bacterial isolates for the prevalence of specific Geno-groups and Geno-types of CTX M enzymes.
METHOD
Sixty-three bacterial isolates were randomly collected during March to April 2013. Fortyseven were G-ve isolates resistant to third generation cephalosporins (3GC) and/or fourthgeneration cephalosporins (4GC) and 16 isolates susceptible to these classes of cephalosporins.
The bacterial identification and antibiotics susceptibility was performed by BD Phoenix-100 automated system.
Isolates were molecularly characterized for CTX M Geno-groups and types by multiplex and monoplex PCRs according to the method described previously 8 . The sets of primers used in this study were targeting blaCTX M group 1, blaCTX M group 2, blaCTX M group 8, blaCTX M group 9 and blaCTX M group 25.
Eighteen (40%), out of which 16 (35.5%) were from group 1 and two (4.5%) were from group 9, were sequenced to confirm the exact type of CTX-M ESBL. The sequencing was performed by Genoscreen. The sequencing results were analyzed by using the Chromas software and BLAST search engine (The Basic Local Alignment Search Tool). Further alignment of the obtained sequences was performed against the specific CTX M types by using the Clustal W software.
Primers used in the PCR reactions and sequencing are shown in Table 1 . 
RESULT
Sixty-three G-ve bacterial isolates were randomly collected from the clinical specimens. The patient-cohort comprised of 20 males and 43 females. The age of the patients ranged from 36 days to 85 years.
Forty-seven were resistant to third generation (3GC) and/or fourth-generation cephalosporin (4GC); 16 G-ve isolates were susceptible to the cephalosporins. These 3GC and/or 4GC resistant and sensitive isolates were further grouped as cephalosporin resistant (CR) and cephalosporin sensitive (CS) groups, for the purpose of analyzing antibiotics susceptibility and molecular results.
Forty-seven (74.6%) clinical specimens, which grew CR isolates, were as follow: 35 (74.5%) urine, 6 (12.8%) pus swab, 4 (8.5%) soft tissue, 1 (2.1%) placental swab and 1 (2.1%) bone tissue. The G-ve isolates obtained from these samples were 41 (87.2%) Escherichia coli, Klebsiella pneumoniae 5 (10.6%) and 1 (2.1%) Proteus vulgaris.
Sixteen clinical specimens, which grew CS isolates were as follow: 11 (68.7%) urine, 4 (25%) pus swab and 1 (6.3%) aspirate. The GNB isolates obtained from these samples were 12 (75%) Escherichia coli, 2 (12.5%) Klebsiella pneumoniae, 1 (6.2%) Enterobacter hermanii and 1 (6.2%) Proteus mirabilis.
The majority of isolates were multiple-drug resistant to cephalosporins fluoroquinolones and aminoglycosides. Maximum resistance was noticed for cephalothin and ampicillin in 61 (96.8%) each, followed by amoxicillin, cefuroxime and ceftriaxone in 50 (79.4%), 49 (77.8%) and 46 (73%) isolates, respectively.
Among aminoglycosides, resistance to gentamicin was noticed in 27 (42.9%) isolates, whereas, only 5 (7.9%) isolates were resistant to amikacin. Among the fluoroquinolones, resistance to levofloxacin was noticed in 32 (50.8%) isolates whereas, the resistance to ciprofloxacin was noticed in 34 (54%) isolates. Cotrimoxazole resistance was 43 (68.3%) in the current collection of G-ve isolates.
All the 63 isolates were sensitive to meropenem; however, resistance to imipenem was noticed in only 1 (1.6%) isolate. Resistance to tigecycline was found in 7 (11.1%) isolates of the present collection.
Significant concomitant resistance to co-trimoxazole 33 (70.2%), ciprofloxacin 28 (59.6%), levofloxacin 26 (55.3%), gentamicin 24 (51.1%) and piperacillin-tazobactam 17 (36.2%) was revealed. The resistance to amikacin in this group was significantly low, 5 (10.6%), and all the isolates of CR group were found sensitive to imipenem and meropenem.
CS group showed significantly high resistance to ampicillin and cephalothin, 14 (87.5%) each. Resistance to amoxicillin and cefuroxime was found in 4 (25%) and 3 (18.6%) isolates. Among fluoroquinolones, 6 (37.5%) isolates showed resistance to ciprofloxacin and levofloxacin. Ten (62.5%) were resistant to co-trimoxazole. All the isolates of this group were sensitive to amikacin, meropenem, ertapenem and piperacillin-tazobactam. One (6.3%) isolate of this group showed resistance to imipenem and tigecycline, see figures 1, 2 and 3. 
DISCUSSION
Acquisition of antibiotics bla genes and conferring resistance to respective classes of antibiotics is a major concern globally these days. Cephalosporins are a widely prescribed antibiotic class, which has shown an increasing resistance globally 1 .
Extended-spectrum -lactamases confer resistance to broad-spectrum cephalosporins and aztreonam. CTX M (Class A) ESBLs are important and extensively studied ESBLs in different parts of the world including Middle East; however, the data from Bahrain regarding this important type of ESBL are fragmentary [9] [10] [11] [12] .
In this pilot study, we noticed that antibiotics resistance in our bacterial population is noteworthy and should not be disregarded. The majority of our isolates were multi-drug resistant.
Our isolates demonstrated significantly high resistance to penicillins/cephalosporins, except cefoxitin, which only 14.3% of isolates demonstrated resistance. Piperacillin-tazobactam showed the resistance in 27% of isolates. Fluoroquinolones showed high resistance rates; levofloxacin showed comparatively lower resistance rate than ciprofloxacin, see figure 1. Among aminoglycosides, amikacin was found to be a better empiric therapeutic option as it showed less resistance (7.9%) in our bacterial population.
These isolates demonstrated consistent sensitivity to carbapenems (imipenem and meropenem), all the isolates were sensitive to meropenem. However, it is alarming to see an emergence of resistance to tigecycline in our bacterial population.
Molecular characterization of the isolates demonstrated that CTX M type of EBLs are highly prevalent (74.6%) in our bacterial population. CTX M 15 was the only CTX M type noticed in this sample. The isolates demonstrating the CTX M group 9 (based on PCR) were nonspecific amplifications and thus suggest that we should not infer the results solely based on PCR data, rather the results should be confirmed by sequencing before inferring a final conclusion.
